What is Frontage Laboratories?
Frontage Laboratories operates as a premier Contract Research Organization (CRO), providing a comprehensive suite of science-driven services that span the entire drug discovery and development lifecycle. The company serves as a vital partner to both emerging biotechnology firms and established pharmaceutical giants, facilitating the advancement of complex molecules from initial research through to regulatory submission. Their service portfolio is extensive, encompassing drug metabolism and pharmacokinetics, analytical testing, formulation development, and preclinical safety and toxicology assessment. Furthermore, the firm provides essential support for clinical trial material manufacturing and early-phase clinical studies, ensuring that clients can navigate the rigorous requirements of global regulatory bodies in the United States, China, and beyond.
How much funding has Frontage Laboratories raised?
Frontage Laboratories has raised a total of $10M across 1 funding round:
Angel/Seed
$10M
Angel/Seed (2008): $10M with participation from Baird Capital Partners Asia
Key Investors in Frontage Laboratories
Baird Capital Partners Asia
Baird Capital is a private equity and venture capital firm that invests in founder-led B2B tech and services companies globally. They manage two distinct investment strategies: Global Private Equity and Venture Capital, focusing on sectors where they possess deep institutional knowledge.
What's next for Frontage Laboratories?
With the infusion of this recent capital, Frontage Laboratories is well-positioned to accelerate its strategic initiatives, particularly in the expansion of its bioanalytical and clinical trial infrastructure. The company is expected to focus on enhancing its technological stack to improve throughput and data precision, which are critical for maintaining a competitive edge in the CRO market. As the pharmaceutical industry continues to prioritize outsourcing for complex development tasks, Frontage is likely to pursue further operational efficiencies and potential service line extensions. This strategic positioning will enable the firm to capture a larger share of the global drug development market while continuing to support the successful commercialization of innovative therapeutic candidates.
See full Frontage Laboratories company page
